EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study

Nils Schulz iD, Thomas Asendorf iD, Pascal van Wijnen iD, Tim Wilhelmi iD, Ulf Müller-Ladner iD, Uwe Lange iD, Philipp Klemm iD

Calcified Tissue International · 2025

DOI: 10.1007/s00223-025-01410-9 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Nils Schulz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Campus Kerckhoff, Benekestr. 2-8,…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Bone Density, Azetidines, Sulfonamides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is associated with systemic bone loss and thus an established risk factor for osteoporosis. Janus kinase inhibitors (JAKi) have shown osteo-protective effects. However, clinical data on the effects of baricitinib on bone mineral density (BMD) remain limited. Therefore, we investigated the effects of a 1-year treatment with baricitinib on BMD in RA patients. Patients with active RA beginning treatment with baricitinib were included. BMD was measured at the lumbar spine and femoral neck using Dual-Energy X-Ray Absorptiometry (DXA). Disease activity was assessed using DAS28-CRP and cDAI. The primary endpoint was the change in BMD after 12 months. Secondary endpoints evaluated changes in disease activity, prednisolone dose and alkaline phosphatase (AP) levels and its relation to BMD. A total of 46 RA patients were recruited, of whom 26 completed the study. Overall, BMD remained stable. Non-responders to baricitinib (based on DAS28-CRP) showed a significant decline in spine BMD (− 2.12%, p = 0.039), while responders showed stable BMD. The between-group difference in spine BMD ( p = 0.008) and T-score ( p = 0.012) was significant. Demographic and clinical characteristics did not differ significantly between groups. Disease activity (DAS28-CRP: p = 0.003; cDAI: p = 0.007), prednisolone dose ( p = 0.006), and AP levels ( p = 0.03) all improved significantly. Under baricitinib, BMD loss appeared stabilized in RA patients. Non-responders to baricitinib experienced a significant loss of BMD with a significant difference to responders raising the question if seen effects are achieved by controlling disease activity or if there is an additional explicit JAKi effect on bone metabolism. Trial registration number: DRKS00020780, date: 13.3.2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidBone DensityAzetidinesSulfonamidesJanus Kinase InhibitorsPyrazolesAntirheumatic AgentsHumansMaleFemaleMiddle AgedPurinesAgedAbsorptiometry, PhotonAdultOsteoporosisTreatment Outcome

Stichwörter der Autor:innen

BaricitinibBone mineral densityJanus kinase inhibitorRheumatoid arthritis

Substanzen

baricitinibAzetidinesPurinesSulfonamidesJanus Kinase InhibitorsPyrazolesAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Campus Kerckhoff, Benekestr. 2-8, 61231, Bad Nauheim, Germany. n.schulz@kerckhoff-klinik.de.
  • Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
  • Department of Rheumatology, Clinical Immunology, Osteology and Physical Medicine, Justus Liebig University Giessen, Campus Kerckhoff, Benekestr. 2-8, 61231, Bad Nauheim, Germany.

ORCID-Profile: Nils Schulz, Thomas Asendorf, Pascal van Wijnen, Tim Wilhelmi, Ulf Müller-Ladner, Uwe Lange, Philipp Klemm

Zitieren

APA

Schulz, N., Asendorf, T., van Wijnen, P., Wilhelmi, T., Müller-Ladner, U., Lange, U., & Klemm, P. (2025). Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01410-9

Vancouver

Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, Müller-Ladner U, Lange U, et al. Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01410-9

BibTeX
@article{Schulz2025,
  author = {Schulz, Nils and Asendorf, Thomas and van Wijnen, Pascal and Wilhelmi, Tim and Müller-Ladner, Ulf and Lange, Uwe and Klemm, Philipp},
  title = {Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study},
  journal = {Calcified Tissue International},
  year = {2025},
  doi = {10.1007/s00223-025-01410-9}
}
Kostenlos starten →